GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (NAS:PODD) » Definitions » Cyclically Adjusted Price-to-FCF

PODD (Insulet) Cyclically Adjusted Price-to-FCF : (As of Jun. 24, 2025)


View and export this data going back to 2007. Start your Free Trial

What is Insulet Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Insulet Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Insulet's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Cyclically Adjusted Price-to-FCF Chart

Insulet Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Insulet Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Insulet's Cyclically Adjusted Price-to-FCF

For the Medical Devices subindustry, Insulet's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insulet's Cyclically Adjusted Price-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Insulet's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Insulet's Cyclically Adjusted Price-to-FCF falls into.


;
;

Insulet Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Insulet's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Insulet's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.649/134.9266*134.9266
=0.649

Current CPI (Mar. 2025) = 134.9266.

Insulet Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 0.009 100.684 0.012
201509 0.109 100.392 0.146
201512 -0.388 99.792 -0.525
201603 -0.240 100.470 -0.322
201606 0.016 101.688 0.021
201609 -0.185 101.861 -0.245
201612 0.299 101.863 0.396
201703 -0.824 102.862 -1.081
201706 0.079 103.349 0.103
201709 0.250 104.136 0.324
201712 -0.129 104.011 -0.167
201803 -0.678 105.290 -0.869
201806 -1.032 106.317 -1.310
201809 -0.356 106.507 -0.451
201812 -0.065 105.998 -0.083
201903 -0.635 107.251 -0.799
201906 -0.613 108.070 -0.765
201909 0.112 108.329 0.139
201912 -0.047 108.420 -0.058
202003 -0.493 108.902 -0.611
202006 0.024 108.767 0.030
202009 0.263 109.815 0.323
202012 -1.055 109.897 -1.295
202103 -1.036 111.754 -1.251
202106 -0.073 114.631 -0.086
202109 -0.790 115.734 -0.921
202112 -0.859 117.630 -0.985
202203 -0.424 121.301 -0.472
202206 0.089 125.017 0.096
202209 0.328 125.227 0.353
202212 -0.526 125.222 -0.567
202303 -0.522 127.348 -0.553
202306 0.369 128.729 0.387
202309 0.456 129.860 0.474
202312 0.162 129.419 0.169
202403 0.862 131.776 0.883
202406 0.970 132.554 0.987
202409 0.938 133.029 0.951
202412 1.238 133.157 1.254
202503 0.649 134.927 0.649

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Insulet  (NAS:PODD) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Insulet Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Insulet's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Insulet Business Description

Traded in Other Exchanges
Address
100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetics are using it worldwide.
Executives
John W. Kapples officer: SVP, Secretary and GC C/O GCP APPLIED TECHNOLOGIES INC., 62 WHITTEMORE AVENUE, CAMBRIDGE MA 02140
Eric Benjamin officer: SVP, R&D, New Prod Dev. & Comm C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DR, SUITE 200, BILLERICA MA 01821
Jessica Hopfield director C/O 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Frederick Wayne A.i. director 500 W MAIN ST., LOUISVILLE KY 40202
Lauren Budden officer: VP, CAO and Controller C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Luciana Borio director C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BLVD., SUITE 315, WOODCLIFF LAKE NJ 07677
Timothy J Scannell director 2825 AIRVIEW BOULEVARD, KALAMAZOO MI 49002
Mark N Field officer: SVP & Chief Technology Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Prem Singh officer: SVP, Global Operations C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Shacey Petrovic officer: CCO 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
James Hollingshead director C/O RESMED INC., 9001 SPECTRUM CENTER BOULEVARD, SAN DIEGO CA 92123
Wayde D. Mcmillan officer: EVP, CFO C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720
Dan Manea officer: SVP, Chief HR Officer C/O INSULET CORPORATION, 100 NAGOG PARK, ACTION MA 01720
Michael R Minogue director 22 CHERRY HILL DR, C/O ABIOMED INC, DANVERS MA 01923
Laetitia Cousin officer: SVP, Reg, Quality & Compliance C/O INSULET CORPORATION, 100 NAGOG PARK, ACTON MA 01720